

PRoFESS Clinical Trial Study

Study title: PRoFESS-Prevention Regimen For Effectively avoiding Second Stroke: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel, with and without Micardis.

Description:

Lutheran Medical Center is one of 206 institutions within the US currently participating in this multinational trial. Twenty-six countries worldwide, including China, The United Kingdom and Australia, are responsible for enrolling the 15,000 patients projected to participate in this trial. Dr. Salman Azhar, Director of LMC Stroke Center and Dr. Anthony Geraci, Attending Neurologist are the investigators for the LMC study site. They believe this study can help make significant strides in the area of stroke prevention.

PRoFESS is a comparative study of Aggrenox vs. Plavix with and without Micardis. Currently, Aggrenox and Plavix are both FDA approved medications that are widely prescribed by physicians for preventing strokes, but it has not been proven which of these two medications is most effective. Micardis is a medication used for hypertension and believed to be highly beneficial for stroke prevention. Patients are screened for the study based on meeting all inclusion criteria. Patients who are accepted will be randomly selected for one of two treatment groups. They will receive either of the two medications at no charge for the duration of the trial.

Stroke prevention is one of the primary objectives of Lutheran Medical Center's Stroke Team. The results of this trial will have a tremendous impact on current treatment practices and provided vital information on methods to effectively prevent strokes.

Inclusion Criteria:

- Male or female, at least 55 years old
- Ischemic stroke within 90 days of enrollment
- Clinical condition is stable